EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Event rates in major Phase 3 heart failure trials over the last 20 years

Alberto Aimo iD, Giorgia Panichella, Andrea Ripoli, Guiomar Mendieta Badimon, Faiez Zannad, Michele Emdin

ESC Heart Failure · 05.05.2026 · 13 (3)

DOI: 10.1093/eschf/xvag169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 11.06.2026. Verfasst von Alberto Aimo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, piazza Martiri della Libertà 33, 56127 Pisa, Italy. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

To determine whether control-arm event rates in heart failure (HF) randomized clinical trials (RCTs) published in New England Journal of Medicine from 2004 to 2024 declined over time, despite intensification of background therapy.

Methods

We identified Phase 3 HF RCTs published in New England Journal of Medicine (2004–24). Annualized event rates were calculated as events divided by patients multiplied by follow-up to the primary endpoint. Temporal trends were analysed with weighted least squares (weights equal to the number of control-arm patients), with adjustment for follow-up duration.

Results

Thirty-eight trials met criteria; 31 enrolled HF with reduced ejection fraction (HFrEF; 82%). In HFrEF control arms, median age was 67 years [interquartile range (IQR) 64–69], women were 24% (IQR 21–30), left ventricular ejection fraction (LVEF) was 28% (25–31), N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 1700 ng/L (1273–2879), and the New York Heart Association (NYHA) class III–IV was 46% (29–71). Background therapy included β-blockers 91% (82–93), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ARBs)/angiotensin receptor–neprilysin inhibitors 93% (90–97), and mineralocorticoid receptor antagonists (MRAs) 52% (42–59). The median control-arm size was 602 patients (308–1533). Across years, therapy use rose (β-blockers +1.04 percentage points per year, P < .001; MRAs +2.05 percentage points per year, P < .001), LVEF increased (+.22% per year, P = .012), NT-proBNP increased (∼+11.4% per year on the log scale, P = .004), and follow-up tended to shorten (P = .052). In control arms, all-cause mortality showed no temporal decline [unadjusted slope +.0019 per year; 95% confidence interval (CI) −.0013 to +.0051; P = .252]; after adjusting for follow-up, the slope was +.0006 per year (P = .711). Longer follow-up was associated with lower annualized mortality (coefficient −.0195 per year; P = .032). Cardiovascular mortality was stable (unadjusted +.0003 per year; 95% CI −.0036 to +.0042; P = .898; follow-up–adjusted −.0012 per year; P = .557). The composite of all-cause death or HF hospitalization increased unadjusted (+.0180 per year; 95% CI +.0063 to +.0298; P = .011) but was not significant after follow-up adjustment (+.0113 per year; P = .111). Enrichment intensity did not rise linearly (coefficient +.032 criteria per year; P = .111), whereas natriuretic-peptide cut-offs were adopted more often [odds ratio (OR) per decade 14.09; 95% CI 1.93–102.75; P = .009). Higher age related to higher mortality (coefficient +.0039 per year; P = .043). An interaction between year and log-transformed NT-proBNP indicated risk-dependent temporal patterns (P = .003).

Conclusion

In major HFrEF trials, control-arm mortality did not decline from 2004 to 2024 despite greater uptake of evidence-based therapy. Risk-enriched enrolment and shorter follow-up likely counterbalanced therapeutic gains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeRandomized Controlled Trials as TopicClinical Trials, Phase III as TopicVentricular Function, LeftHumansFemaleNatriuretic Peptide, Brain

Stichwörter der Autor:innen

Heart failureMortalityRandomized controlled trialsSurvivalTherapyTrial design

Substanzen

Natriuretic Peptide, Brain

Autor:innen und Institutionen

  • Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, piazza Martiri della Libertà 33, 56127 Pisa, Italy.
  • Cardiology Division, Fondazione Toscana Gabriele Monasterio, via Moruzzi 1, 56124 Pisa, Italy.
  • Cardiology Department, Careggi University Hospital, Largo G.A. Brambilla 3, 50134 Florence, Italy.
  • Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), CIBER CV, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
  • Université de Lorraine, Nancy, France.

ORCID-Profile: Alberto Aimo

Zitieren

APA

Aimo, A., Panichella, G., Ripoli, A., Mendieta Badimon, G., Zannad, F., & Emdin, M. (2026). Event rates in major Phase 3 heart failure trials over the last 20 years. ESC Heart Failure, 13(3). https://doi.org/10.1093/eschf/xvag169

Vancouver

Aimo A, Panichella G, Ripoli A, Mendieta Badimon G, Zannad F, Emdin M. Event rates in major Phase 3 heart failure trials over the last 20 years. ESC Heart Failure. 2026;13(3). doi:10.1093/eschf/xvag169

BibTeX
@article{Aimo2026,
  author = {Aimo, Alberto and Panichella, Giorgia and Ripoli, Andrea and Mendieta Badimon, Guiomar and Zannad, Faiez and Emdin, Michele},
  title = {Event rates in major Phase 3 heart failure trials over the last 20 years},
  journal = {ESC Heart Failure},
  year = {2026},
  volume = {13},
  number = {3},
  doi = {10.1093/eschf/xvag169}
}
Kostenlos starten →